Bristol-Myers Squibb (NYSE:BMY) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases. During the most recent period, it announced a multibillion-dollar financial investment to establish a multimodal manufacturing campus located in Texas, while also securing an accelerated regulatory approval from the FDA for a combination therapy intended to treat multiple myeloma. Novo Nordisk (NYSE:NVO) earns most of its revenue by manufacturing and globally distributing medical treatments for diabetes and obesity.
CryptoAlerta — análise de criptomoedas e mercado em tempo real